AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04069689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPX-100 (Clemizole Hydrochloride)
Description: EPX-100 (Clemizole Hydrochloride)
Study NCT04069689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo to match EPX-100
Study NCT00496522 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Proton Beam Therapy
Description: A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
Study NCT03474588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment (ST) PLUS web-based CBT4CBT
Description: Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on
Study NCT03474588 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment (ST)
Description: ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
Study NCT04142606 — intervention group
Intervention type: OTHER
Intervention: fetal MRI
Description: The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)
Study NCT02979392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)
Description: TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
Study NCT03940352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: Capsule
Study NCT03940352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBG453
Description: LIVI (Liquid in vial) Concentrate for Solution for infusion
Study NCT03940352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet
Study NCT00292721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: celecoxib: loading and maintenance for 6 months
Study NCT01553331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dissection of gallbladder in laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
Study NCT01553331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dissection of gallbladder in laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
Study NCT03430531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
Study NCT01435616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Study NCT01435616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study NCT04483505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination, Rogaratinib + palbociclib + fulvestrant
Description: Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.~Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:~* Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).~* Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).~Treatment will continue until disease progression.
Study NCT03451682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: procyanidine
Description: Natural antioxidant
Study NCT00968227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Description: Transfusion of 1 unit of packed red blood cells over 1 hour.
Study NCT01462123 — intervention group
Intervention type: OTHER
Intervention: endoscopic assessment of colonic polyps
Study NCT03891693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux and SUPERA® stent
Description: Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis
Study NCT04648644 — intervention group
Intervention type: OTHER
Intervention: Application of ERAS protocol
Description: Application of a standardized ERAS protocol for the perioperative perioperative management of patients undergoing emergency surgery
Study NCT04051736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Polio Vaccine
Description: Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
Study NCT04051736 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Polio Vaccine
Description: Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
Study NCT00989534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed restricted bedtimes
Description: Sleep restricted to 5 hours per night for 8 nights
Study NCT00989534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction with circadian misalignment
Description: Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
Study NCT00528645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally
Study NCT01489891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
Study NCT01489891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
Study NCT04463966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: 1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
Study NCT02022189 — intervention group
Intervention type: PROCEDURE
Intervention: Renal Biopsy
Study NCT04218149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Block with bupivacaine
Study NCT01581138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: 400 mg tablets twice daily for oral administration
Study NCT01581138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: 1125 mg tablets twice daily for oral administration
Study NCT01581138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
Study NCT02383004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
Study NCT03548532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G210 incubator
Description: very stable culture temperature, up to 0.1°C, in both arms
Study NCT02097901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Rotator Cuff Repair AND Microfracture
Study NCT02097901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NO microfracture
Description: Rotator Cuff Repair without microfracture
Study NCT03948165 — intervention group
Intervention type: PROCEDURE
Intervention: Distal Transradial Access
Description: The distal radial artery needs to be punctured with specialized equipment with a 20, 21 or 22-gauge puncture needle, using a transfixion or anterior wall technique. A 0.025 in, 46 cm guide was introduced in the system, followed by the introduction of the 5 Fr, 6 Fr, 7Fr hydrophilic arterial sheath or 5 Fr, 6 Fr or 7 Fr Glidesheath Slender introducer (TerumoIS, Tokyo, Japan), after a small incision in the skin.
Study NCT01970345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1
Description: IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
Study NCT03548532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G210 incubator
Description: very stable culture temperature, up to 0.1°C, in both arms
Study NCT04205227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENB003
Description: ENB003 is selective Endothelin B Receptor Antagonist
Study NCT04205227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD1
Study NCT02023086 — intervention group
Intervention type: PROCEDURE
Intervention: Contrast sensitivity measurement
Description: Contrast sensitivity test is made with targets alternating black and white lines. The larger the lines are, easier it is to see them. Targets are distributed in 5 rows, each oriented at a different angle. Contrast sensitivity level is determined by the smallest target seen by the participant, line by line. This test is done under dim lightning with the habitual visual correction worn.
Study NCT02023086 — intervention group
Intervention type: PROCEDURE
Intervention: Slit Lamp assessment and intra-ocular pressure measurement
Description: Slit lamp is used to assess the presence of significant lens opacities known as Fabry cataracts. In fact, these opacities can induced a bias on the contrast sensitivity measurement and can increase the symptoms felt by the patient. A grade 2 (CFDI grading chart) of lens opacities is considered clinically significant and this will become an exclusion criteria for the following of the study. Intra-ocular pressure will be measured with a non contact tonometer (air pulsed) (Ocular Response Analyser, Reichert Instrumentation.)
Study NCT02023086 — intervention group
Intervention type: PROCEDURE
Intervention: Visual field testing
Description: Visual field will be assessed with an automated perimeter (Humphrey, Texas) using a threshold strategy. This implies that the subject has to identify not only if he perceives the visual stimulus but the minimal level of this stimulus (in decibels), to be seen, is also recorded. Visual field will be tested up to 30 degrees from the central point of fixation.~In order to measure immediate variability of the visual testing among Fabry subjects, this test will be done at the beginning of the testing session (in the morning) and another time 1h00 later.
Study NCT02023086 — intervention group
Intervention type: PROCEDURE
Intervention: Oxygen flow at the optic nerve head measurement
Description: Pupils will be dilated with 1 drop of 1% tropicamide. The procedure is similar to the one used for taking a photo of the retina. Each measurement session represents a continuous recording of 20 simultaneous functions of reflectometry from the optic nerve area during 10 seconds.~During all recording sessions, the systemic arterial oxygen saturation will be also monitored at the right index finger using a pulse oximeter (Escort M10, Invivo, Orlando, USA). Arterial blood pressure will be also monitored before and after the testing using a manual sphygmomanometer.
Study NCT02023086 — intervention group
Intervention type: DRUG
Intervention: Tropicamide
Description: Used to dilate patient's pupil during testing
Study NCT02023086 — intervention group
Intervention type: DEVICE
Intervention: OSOME
Description: The OSOME system is the only technology able to perform on line and real time capillaries blood oxygenation measurement in the eye. The system operates with 1200 discreet wavelengths between 400 nm to 700 nm with 500 millisecond integration times. It is not invasive, functioning just like a fundus camera.
Study NCT01885299 — intervention group
Intervention type: RADIATION
Intervention: SRS/SBRT
Description: Intervention varies by condition being treated.
Study NCT03641755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Sapacitabine may help to stop the growth of some types of cancers
Study NCT03641755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working
Study NCT04504253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate loose powder
Study NCT04504253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
Study NCT03527420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Twelve weeks of aerobic exercise training
Study NCT04965025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-stage urethroplasty with graft inlay in first stage
Description: Herein, the graft will be used in the first stage and the second stage will solely consist of retubularizing the urethra.
Study NCT04965025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-stage urethroplasty with graft inlay in second stage
Description: Herein, the graft will be used in the second stage and the first stage will solely consist of opening the urethra longitudinally.
Study NCT03723655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules
Study NCT03733626 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system
Description: ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion.
Study NCT03733626 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system
Description: Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion.
Study NCT05813574 — intervention group
Intervention type: OTHER
Intervention: Observational patient reported outcomes
Description: Of COVID-19 patients
Study NCT01970345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/saline
Description: Placebo
Study NCT02819830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Combined strength and aerobic exercise
Study NCT03461276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABvac40
Description: ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminium hydroxide as adjuvant.
Study NCT03461276 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminium hydroxide) without the conjugate.
Study NCT00538200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplements (Fortisip)
Description: These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
Study NCT00538200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Advice
Description: Standard dietary advice
Study NCT00542243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride (5mg) will be given once per day for 6 months.
Study NCT00542243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given once a day for 6 months.
Study NCT06520254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: A 30-minute massage session will be applied in the following structures:~* Flexor hallucis longus muscle,~* Flexor digitorum longus muscle,~* Tibialis posterior muscle,~* Semitendinosus muscle,~* Semimembranosus muscle,~* Gluteus maximus muscle,~* Longissimus muscle,~* Levator costarum muscles 1-5 During the massage session basic Swedish massage techniques were used.
Study NCT04540250 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: conventional intra-oral examination and questionnaire
Study NCT04805229 — intervention group
Intervention type: OTHER
Intervention: Retrospective analysis of opioid use after surgery
Description: Retrospective analysis of opioid use after one of the following surgical procedure categories: laparoscopic cholecystectomy, laparoscopic appendectomy, minor hernia repair (including laparoscopic or open inguinal, femoral, umbilical, and epigastric hernia repair), open and laparoscopic ventral/incisional hernia repair, laparoscopic colectomy, open colectomy, vaginal hysterectomy, laparoscopic hysterectomy, and open abdominal hysterectomy.
Study NCT00267904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Caffeinated coffee and decaffeinated coffee ingestion
Study NCT00267904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banana
Description: Banana ingestion
Study NCT00267904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olives
Description: Olives ingestion
Study NCT00267904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temp. manip.
Description: Manipulate temperature at skin of the back
Study NCT00994084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Kids-Houston program
Description: Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
Study NCT00994084 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
Study NCT01425424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Vitamin D
Study NCT01853644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: 1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
Study NCT02657512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban 40 mg/day (1 day)
Study NCT02657512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban and activated charcoal
Description: rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
Study NCT01177579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Copper gluconate
Description: 4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
Study NCT00619203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol and paracetamol
Description: glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7
Study NCT00619203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
Study NCT00619203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
Study NCT00619203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
Study NCT00619203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebos, one po, one suppository
Study NCT00619203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol and glycerol
Description: 35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses
Study NCT00619203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol
Description: glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml